Financing ·
Alvotech entered into an Underwriting Agreement on June 15, 2026, for a public offering of 22,666,667 ordinary shares…
ALVOAlvotech
Alvotech entered into an Underwriting Agreement on June 15, 2026, for a public offering of 22,666,667 ordinary shares at $3.75 per share, with an additional 3,400,000 shares option exercised in full. The company also entered into subscription agreements for a private placement of 17,826,666 shares at the same price, which is expected to close within seven business days of the public offering. Net proceeds from the public offering are expected to be approximately $91.20 million. Alvotech is a biotechnology company focused on developing and manufacturing biosimilars.